How an Unproven Alzheimer’s Drug Got Approved
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.
Read Full Article »
Comment
Show comments
Hide Comments
